{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:35:55Z","timestamp":1790631355373,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,21]]},"DOI":"10.7759\/cureus.45726","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T21:11:27Z","timestamp":1695330687000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of the Surgery-First Approach Compared to the Chemotherapy-First Approach for Treating Low-Risk Gestational Trophoblastic Neoplasia: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Kyosuke","family":"Kamijo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Oide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Anan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Taito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenro","family":"Chikazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004240","article-title":"Gestational trophoblastic disease: current evaluation and management","volume":"137","author":"Soper JT","year":"2021","unstructured":"Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 2021, 137:355-70. 10.1097\/AOG.0000000000004240","journal-title":"Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0020-7292(03)90120-2","article-title":"Gestational trophoblastic neoplasia, FIGO 2000 staging and classification","volume":"83","author":"Ngan HY","year":"2003","unstructured":"Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S; FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003, 83:175-7. 10.1016\/s0020-7292(03)90120-2","journal-title":"Int J Gynaecol Obstet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(02)00063-2","article-title":"FIGO staging for gestational trophoblastic neoplasia 2000: FIGO Oncology Committee","volume":"77","author":"Figo Oncology Committee","year":"2002","unstructured":"Figo Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000: FIGO Oncology Committee. Int J Gynaecol Obstet. 2002, 77:285-7. 10.1016\/S0020-7292(02)00063-2","journal-title":"Int J Gynaecol Obstet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.10.028","article-title":"Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience","volume":"148","author":"Maest\u00e1 I","year":"2018","unstructured":"Maest\u00e1 I, Nitecki R, Horowitz NS, Goldstein DP, de Freitas Segalla Moreira M, Elias KM, Berkowitz RS. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018, 148:161-7. 10.1016\/j.ygyno.2017.10.028","journal-title":"Gynecol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601422","article-title":"Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects","volume":"89","author":"Khan F","year":"2003","unstructured":"Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer. 2003, 89:2197-201. 10.1038\/sj.bjc.6601422","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0053","article-title":"Gestational trophoblastic neoplasia, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Abu-Rustum NR","year":"2019","unstructured":"Abu-Rustum NR, Yashar CM, Bean S, et al.. Gestational trophoblastic neoplasia, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019, 17:1374-91. 10.6004\/jnccn.2019.0053","journal-title":"J Natl Compr Canc Netw"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13617","article-title":"Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review","volume":"123","author":"Braga A","year":"2016","unstructured":"Braga A, Maest\u00e1 I, Short D, Savage P, Harvey R, Seckl MJ. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review. BJOG. 2016, 123:1330-5. 10.1111\/1471-0528.13617","journal-title":"BJOG"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0037-6","article-title":"Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study","volume":"118","author":"Kim JW","year":"2018","unstructured":"Kim JW, Lee YG, Hwang IG, et al.. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. Br J Cancer. 2018, 118:1169-75. 10.1038\/s41416-018-0037-6","journal-title":"Br J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2020.03.001","article-title":"Guideline No. 408: Management of gestational trophoblastic diseases","volume":"43","author":"Eiriksson L","year":"2021","unstructured":"Eiriksson L, Dean E, Sebastianelli A, et al.. Guideline No. 408: Management of gestational trophoblastic diseases. J Obstet Gynaecol Can. 2021, 43:91-105.e1. 10.1016\/j.jogc.2020.03.001","journal-title":"J Obstet Gynaecol Can"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S139226","article-title":"A pilot randomized controlled clinical trial of second uterine curettage versus usual care to determine the effect of re-curettage on patients' need for chemotherapy among women with low risk, nonmetastatic gestational trophoblastic neoplasm in Urmia, Iran","volume":"9","author":"Ayatollahi H","year":"2017","unstructured":"Ayatollahi H, Yekta Z, Afsari E. A pilot randomized controlled clinical trial of second uterine curettage versus usual care to determine the effect of re-curettage on patients' need for chemotherapy among women with low risk, nonmetastatic gestational trophoblastic neoplasm in Urmia, Iran. Int J Womens Health. 2017, 9:665-71. 10.2147\/IJWH.S139226","journal-title":"Int J Womens Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003232","article-title":"Second uterine curettage and the number of chemotherapy courses in postmolar gestational trophoblastic neoplasia: a randomized controlled trial","volume":"133","author":"Hemida R","year":"2019","unstructured":"Hemida R, Vos EL, El-Deek B, Arafa M, Toson E, Burger CW, van Doorn HC. Second uterine curettage and the number of chemotherapy courses in postmolar gestational trophoblastic neoplasia: a randomized controlled trial. Obstet Gynecol. 2019, 133:1024-31. 10.1097\/AOG.0000000000003232","journal-title":"Obstet Gynecol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.06.032","article-title":"The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey","volume":"99","author":"van Trommel NE","year":"2005","unstructured":"van Trommel NE, Massuger LF, Verheijen RH, Sweep FC, Thomas CM. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005, 99:6-13. 10.1016\/j.ygyno.2005.06.032","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.003","article-title":"Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia","volume":"112","author":"Growdon WB","year":"2009","unstructured":"Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol. 2009, 112:353-7. 10.1016\/j.ygyno.2008.11.003","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.05.030","article-title":"First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive","volume":"150","author":"Bolze PA","year":"2018","unstructured":"Bolze PA, Mathe M, Hajri T, et al.. First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive. Gynecol Oncol. 2018, 150:282-7. 10.1016\/j.ygyno.2018.05.030","journal-title":"Gynecol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-021-01328-2","article-title":"Role of hysterectomy in gestational trophoblastic neoplasia","volume":"12","author":"Ramesan CK","year":"2021","unstructured":"Ramesan CK, Thomas DS, Sebastian A, Thomas V, Thomas A, George R, Peedicayil A. Role of hysterectomy in gestational trophoblastic neoplasia. Indian J Surg Oncol. 2021, 12:386-90. 10.1007\/s13193-021-01328-2","journal-title":"Indian J Surg Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5539\/jmbr.v10n1p88","article-title":"The curative effect of a second curettage in low-risk gestational trophoblastic neoplasia","volume":"10","author":"Ahmadzadeh A","year":"2020","unstructured":"Ahmadzadeh A, Najafian M, Lalvand, K. The curative effect of a second curettage in low-risk gestational trophoblastic neoplasia. J Mol Biol Res. 2020, 10:88-93. 10.5539\/jmbr.v10n1p88","journal-title":"J Mol Biol Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021, 88:105906. 10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"ref18","unstructured":"Effectiveness and safety of various interventions for the treatment of low-risk gestational trophoblastic neoplasia. A systematic review and network meta-analysis protocol. (2021). Accessed: September 1, 2023: https:\/\/osf.io\/bdtqn\/."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014755","article-title":"Fertility\u2010sparing, surgical interventions for low\u2010risk, non\u2010metastatic gestational trophoblastic neoplasia","volume":"2022","author":"Boonyapipat S","year":"2022","unstructured":"Boonyapipat S, Nanthamongkolkul K, Saeaib N, Liabsuetrakul T. Fertility\u2010sparing, surgical interventions for low\u2010risk, non\u2010metastatic gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2022, 2022:CD014755. 10.1002\/14651858.CD014755","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref22","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2019","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Chichester; 2019."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan X","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014, 14:135. 10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa TA","year":"2006","unstructured":"Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006, 59:7-10. 10.1016\/j.jclinepi.2005.06.006","journal-title":"J Clin Epidemiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt G","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al.. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64:383-94. 10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00262-X","article-title":"Predictors for single-agent resistance in Figo score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study","volume":"22","author":"Braga A","year":"2021","unstructured":"Braga A, Paiva G, Ghorani E, et al.. Predictors for single-agent resistance in Figo score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021, 22:1188-98. 10.1016\/S1470-2045(21)00262-X","journal-title":"Lancet Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.06.072","article-title":"Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia","volume":"204","author":"Lurain JR","year":"2011","unstructured":"Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011, 204:11-8. 10.1016\/j.ajog.2010.06.072","journal-title":"Am J Obstet Gynecol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12615","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143 Suppl 2","author":"Ngan HY","year":"2018","unstructured":"Ngan HY, Seckl MJ, Berkowitz RS, et al.. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018, 143 Suppl 2:79-85. 10.1002\/ijgo.12615","journal-title":"Int J Gynaecol Obstet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl MJ","year":"2010","unstructured":"Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010, 376:717-29. 10.1016\/S0140-6736(10)60280-2","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/1740774508091600","article-title":"Imputation methods for missing outcome data in meta-analysis of clinical trials","volume":"5","author":"Higgins JP","year":"2008","unstructured":"Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clin Trials. 2008, 5:225-39. 10.1177\/1740774508091600","journal-title":"Clin Trials"},{"key":"ref31","unstructured":"Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia. (2020). Accessed. September 1, 2023: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03703271."},{"key":"ref32","unstructured":"Second uterine evacuation for low-risk gestational trophoblastic neoplasia (ReCure). (2022). Accessed. September 1, 2023: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04756713."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.47176\/mjiri.37.27","article-title":"Repeat curettage in the management of low-risk gestational trophoblastic neoplasia (GTN)","volume":"37","author":"Aminimoghaddam S","year":"2023","unstructured":"Aminimoghaddam S, Chaichian S, Kashian M, Mohazzab A, Pourali R. Repeat curettage in the management of low-risk gestational trophoblastic neoplasia (GTN). Med J Islam Repub Iran. 2023, 37:27. 10.47176\/mjiri.37.27","journal-title":"Med J Islam Repub Iran"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001554","article-title":"Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia","volume":"128","author":"Osborne RJ","year":"2016","unstructured":"Osborne RJ, Filiaci VL, Schink JC, et al.. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol. 2016, 128:535-42. 10.1097\/AOG.0000000000001554","journal-title":"Obstet Gynecol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.52764\/jms.22.30.2.3","article-title":"Pregnancy outcomes after chemotherapy for gestational trophoblast neoplasia","volume":"30","author":"Bangash AG","year":"2022","unstructured":"Bangash AG, Tabassum S, Afridi F, et al.. Pregnancy outcomes after chemotherapy for gestational trophoblast neoplasia. J Med Sci. 2022, 30:117-20. 10.52764\/jms.22.30.2.3","journal-title":"J Med Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5839","article-title":"Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy","volume":"78","author":"Tidy JA","year":"2000","unstructured":"Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol. 2000, 78:309-12. 10.1006\/gyno.2000.5839","journal-title":"Gynecol Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.08.045","article-title":"The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease","volume":"95","author":"Pezeshki M","year":"2004","unstructured":"Pezeshki M, Hancock BW, Silcocks P, et al.. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol. 2004, 95:423-9. 10.1016\/j.ygyno.2004.08.045","journal-title":"Gynecol Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)90907-O","article-title":"Diagnostic and therapeutic curettage in gestational trophoblastic disease","volume":"162","author":"Schlaerth JB","year":"1990","unstructured":"Schlaerth JB, Morrow CP, Rodriguez M. Diagnostic and therapeutic curettage in gestational trophoblastic disease. Am J Obstet Gynecol. 1990, 162:1465-71. 10.1016\/0002-9378(90)90907-O","journal-title":"Am J Obstet Gynecol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7863\/jum.1989.8.2.71","article-title":"Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation","volume":"8","author":"Darney PD","year":"1989","unstructured":"Darney PD, Sweet RL. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. J Ultrasound Med. 1989, 8:71-5. 10.7863\/jum.1989.8.2.71","journal-title":"J Ultrasound Med"},{"key":"ref40","article-title":"The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center","volume":"55","author":"Clark RM","year":"2010","unstructured":"Clark RM, Nevadunsky NS, Ghosh S, et al.. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med. 2010, 55:194-8.","journal-title":"J Reprod Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(00)01169-8","article-title":"Adjuvant hysterectomy in low-risk gestational trophoblastic disease","volume":"97","author":"Suzuka K","year":"2001","unstructured":"Suzuka K, Matsui H, Iitsuka Y, Yamazawa K, Seki K, Sekiya S. Adjuvant hysterectomy in low-risk gestational trophoblastic disease. Obstet Gynecol. 2001, 97:431-4. 10.1016\/S0029-7844(00)01169-8","journal-title":"Obstet Gynecol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/187748-efficacy-and-safety-of-the-surgery-first-approach-compared-to-the-chemotherapy-first-approach-for-treating-low-risk-gestational-trophoblastic-neoplasia-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:20Z","timestamp":1707509300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/187748-efficacy-and-safety-of-the-surgery-first-approach-compared-to-the-chemotherapy-first-approach-for-treating-low-risk-gestational-trophoblastic-neoplasia-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.45726","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}